Compare BODI & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BODI | RNAZ |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3M | 27.9M |
| IPO Year | 2020 | 2021 |
| Metric | BODI | RNAZ |
|---|---|---|
| Price | $4.27 | $1.55 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $16.25 | N/A |
| AVG Volume (30 Days) | 11.3K | ★ 29.4K |
| Earning Date | 11-10-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.10 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $251,727,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.09 | N/A |
| P/E Ratio | $9.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.01 | $1.52 |
| 52 Week High | $16.87 | $12.60 |
| Indicator | BODI | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 38.38 |
| Support Level | $4.01 | $1.57 |
| Resistance Level | $5.11 | $1.95 |
| Average True Range (ATR) | 0.23 | 0.15 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 47.22 | 11.45 |
The Beachbody Co Inc is a fitness and nutrition company providing fitness, nutrition, and stress-reducing programs to its customers. a results-oriented company at the intersection of wellness, technology, and media. The company developed one of the original fitness digital streaming platforms with an extensive library of content containing streaming programs and streaming videos. Company products include Digital Subscriptions, Nutritional Products, and Connected Fitness Products, where the majority of revenue is from Digital Subscriptions. The Company has one operating and reporting segment. Geographically operates in the USA and the rest of the world, with maximum revenue from the United States.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.